Metronimics with Cyclophosphamide (Cy) and Losartan (Los) for the treatment of M-406 triple negative murine mammary adenocarcinoma.

GRILLO, MÓNICA CAROLINA; KAUFMAN, CINTIA DANIELA ; DEL GIÚDICE, ANTONELA; BAGLIONI, MARÍA VIRGINIA; ROZADOS, VIVIANA ROSA; SCHAROVSKY, OLGA GRACIELA; RICO, MARÍA JOSE; MAINETTI, LEANDRO ERNESTO

Mar del Plata

Congreso; LXIII Reunión anual de la Sociedad Argentina de Investigación Clínica (SAIC); 2018

Sociedad Argentina de Investigación Clínica

Metronomic chemotherapy (MCT) refers to the chronic, equally spaced, delivery of low doses of chemotherapeutic drugs, without extended interruptions. Drug repositioning (DR) in oncology makemention of the use of drugs originally formulated for other indications that showed antitumor potential. "Metronomics" is defined as the combination of MCT and DR. Cy is an alkylating drug with toxicaction on proliferating cells. Los is an antagonist of angiotensin II receptor, used to treat hypertension. Our aim was to study the effect of metronomic Cy+Los treatment, on M-406 bearing animals. CBi female mice were challenged s.c. with M-406 (day 0) and distributed on day 6, into 4 groups (n=6-7/group). GI: Control, non-treated; GII: Treated with Cy 25mg/kg/day in the drinking water; GIII: Treated with Los 150mg/kg/day in the drinking water; GIV: Treated as GII+GIII. Mice were weighted and tumor volume measured, 3 times/week. When tumors were exponentially growing, mice were euthanized, and blood samples were taken to evaluate immune cells populations. On day 21, tumor volume in GIV (mm3, mean ± SEM:284.4± 91.4) was lower than in GI (3552±745.7), GII (1101±344.3) and GIII (1033±306.6) (P